The estimated Net Worth of Carmen Jeffrey Del is at least 1.73 百万$ dollars as of 9 August 2024. Mr Del owns over 36,058 units of Catalyst Pharmaceuticals Inc stock worth over 240,701$ and over the last 4 years he sold CPRX stock worth over 984,039$. In addition, he makes 507,957$ as Chief Commercial Officer at Catalyst Pharmaceuticals Inc.
Sign up
Mr Carmen CPRX stock SEC Form 4 insiders trading
Mr has made over 11 trades of the Catalyst Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 36,058 units of CPRX stock worth 664,188$ on 9 August 2024.
The largest trade he's ever made was exercising 139,017 units of Catalyst Pharmaceuticals Inc stock on 11 November 2022 worth over 386,467$. On average, Mr trades about 18,547 units every 71 days since 2020. As of 9 August 2024 he still owns at least 12,369 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr Del stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jeffrey Del Carmen biography
Jeffrey Del Carmen is the Chief Commercial Officer at Catalyst Pharmaceuticals Inc.
What is the salary of Mr Carmen?
As the Chief Commercial Officer of Catalyst Pharmaceuticals Inc, the total compensation of Mr Carmen at Catalyst Pharmaceuticals Inc is 507,957$. There are 8 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of 3,371,560$.
How old is Mr Carmen?
Mr Carmen is 50, he's been the Chief Commercial Officer of Catalyst Pharmaceuticals Inc since . There are 13 older and 2 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
What's Mr Carmen's mailing address?
Carmen's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134.
Insiders trading at Catalyst Pharmaceuticals Inc
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over 35,595,986$ worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth 7,307,159$ . The most active insiders traders include Pharmaceutical Inc Biomarin、Patrick J Mcenany、Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 1,097,019$. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth 60,150$.
What does Catalyst Pharmaceuticals Inc do?
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
What does Catalyst Pharmaceuticals Inc's logo look like?
Complete history of Mr Del stock trades at Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc executives and stock owners
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Patrick McEnany,
Chairman of the Board, President, Chief Executive Officer -
Steven Miller,
Chief Operating Officer, Chief Scientific Officer -
Gary Ingenito,
Chief Medical Officer and Head of Regulatory Affairs -
Patrick J. McEnany,
Co-Founder, Chairman, Pres & CEO -
Dr. Steven R. Miller,
COO & Chief Scientific Officer -
Dr. Gary Ingenito,
Chief Medical & Regulatory Officer -
Alicia Grande,
Chief Accounting Officer, VP, Treasurer & CFO -
Alicia Grande,
Chief Financial Officer, Vice President, Treasurer -
Jeffrey Del Carmen,
Chief Commercial Officer -
Brian Elsbernd,
Chief Compliance Officer, Chief Legal Officer -
Charles O'Keeffe,
Lead Independent Director -
Donald Denkhaus,
Independent Director -
David Tierney,
Independent Director -
Richard Daly,
Independent Director -
Jeffrey Del Carmen,
Chief Commercial Officer -
Philip B. Schwartz,
Corp. Sec. -
Dr. Preethi Sundaram Ph.D.,
Chief Product Devel. Officer -
Pete Curry Sr.,
VP of Sales -
Brian Elsbernd J.D.,
Chief Compliance Officer & Chief Legal Officer -
Mary Coleman,
VP & Head of Investor Relations -
Philip H Coelho,
Director -
Paul J Merrigan,
Chief Commercial Officer -
M Douglas Winship,
V.P. of Regulatory Operations -
Daniel Brennan,
Chief Commercial Officer -
Tamar Thompson,
Director -
David D Muth,
Exec. V.P., Corp. Development -
Hubert E Md Huckel,
Director -
Milton J Wallace,
Director -
Pharmaceutical Inc Biomarin,
10% owner -
Jack Weinstein,
V.P., Treasurer & CFO -
Molly Harper,
Director -
Preethi Sundaram,
Chief Strategy Officer -
Steve Miller,
Chief Op. & Scientific Officer